Search
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read moreFirst randomized evidence for kinase inhibitor activity in acute myeloid leukemia
Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).
Read moreDo generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.
The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.
Gdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.
EHA Blood Cancer Awareness Month Wrap-up
The first European Hematology Association (EHA) Blood Cancer Awareness Month digital campaign aimed to raise awareness of hematological malignancies and EHA’s commitment “towards a cure for all blood disorders”.
Read moreSWG Educational Activities
SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.
Read moreEHA reaffirms commitment to hematology's future with new brand identity
The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.
Read moreEHA Issues Recommendations on Mild to Moderate Bleeding Disorders
HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems
For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems – or even to determine whether there is any bleeding…
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- »